PUMA BIOTECHNOLOGY, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$40.00 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-10
- PUMA BIOTECHNOLOGY, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$40.00K.
- PUMA BIOTECHNOLOGY, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$23.52M, a 212.88% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was $44.08M, a 49.58% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $18.08M, a 73.39% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$15.44M, a 110.86% decline from fiscal 2016.
- PUMA BIOTECHNOLOGY, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $142.19M.
- PUMA BIOTECHNOLOGY, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$85.86M.
- PUMA BIOTECHNOLOGY, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$63.27M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 42 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 45 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 48 month |
|---|---|---|---|---|---|---|---|---|
| 2018-03-31 | -$40.00K 10-Q · filed 2018-05-10 | -$23.56M derived: sum of 2 quarters · filed 2018-05-10 | $20.52M derived: sum of 3 quarters · filed 2018-05-10 | $38.60M derived: sum of 4 quarters · filed 2018-05-10 | ||||
| 2017-12-31 | -$23.52M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $20.56M derived: sum of 2 quarters · filed 2018-03-09 | $38.64M derived: sum of 3 quarters · filed 2018-03-09 | -$15.44M 10-K · filed 2018-03-09 | ||||
| 2017-09-30 | $44.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $62.16M derived: sum of 2 quarters · filed 2017-11-09 | $8.08M 10-Q · filed 2017-11-09 | $28.92M derived: sum of 4 quarters · filed 2018-05-10 | ||||
| 2017-06-30 | $18.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$35.99M 10-Q · filed 2017-08-09 | -$15.16M derived: sum of 3 quarters · filed 2018-05-10 | $14.31M derived: sum of 4 quarters · filed 2018-05-10 | ||||
| 2017-03-31 | -$54.07M 10-Q · filed 2018-05-10 | -$54.07M 10-Q · filed 2017-05-10 | -$33.24M derived: sum of 2 quarters · filed 2018-05-10 | -$3.77M derived: sum of 3 quarters · filed 2018-05-10 | $6.66M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2016-12-31 | $20.84M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $50.30M derived: sum of 2 quarters · filed 2018-03-09 | $60.73M derived: sum of 3 quarters · filed 2018-03-09 | $142.19M 10-K · filed 2018-03-09 | ||||
| 2016-09-30 | $29.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $39.89M derived: sum of 2 quarters · filed 2017-11-09 | $121.35M 10-Q · filed 2017-11-09 | $161.03M derived: sum of 4 quarters · filed 2018-03-09 | ||||
| 2016-06-30 | $10.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $91.88M 10-Q · filed 2017-08-09 | $131.56M derived: sum of 3 quarters · filed 2018-03-09 | $126.82M derived: sum of 4 quarters · filed 2018-03-09 | ||||
| 2016-03-31 | $81.46M 10-Q · filed 2017-05-10 | $121.14M derived: sum of 2 quarters · filed 2018-03-09 | $116.39M derived: sum of 3 quarters · filed 2018-03-09 | $48.28M derived: sum of 4 quarters · filed 2018-03-09 | ||||
| 2015-12-31 | $39.68M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $34.94M derived: sum of 2 quarters · filed 2018-03-09 | -$33.18M derived: sum of 3 quarters · filed 2018-03-09 | -$85.86M 10-K · filed 2018-03-09 | ||||
| 2015-09-30 | -$4.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$72.86M derived: sum of 2 quarters · filed 2016-11-09 | -$125.55M 10-Q · filed 2016-11-09 | -$103.34M derived: sum of 4 quarters · filed 2017-03-01 | ||||
| 2015-06-30 | -$68.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$120.80M 10-Q · filed 2016-08-09 | -$98.59M derived: sum of 3 quarters · filed 2017-03-01 | -$101.37M derived: sum of 4 quarters · filed 2017-03-01 | ||||
| 2015-03-31 | -$52.68M 10-Q · filed 2016-05-10 | -$30.48M derived: sum of 2 quarters · filed 2017-03-01 | -$33.25M derived: sum of 3 quarters · filed 2017-03-01 | -$123.90M derived: sum of 4 quarters · filed 2017-03-01 | ||||
| 2014-12-31 | $22.20M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $19.43M derived: sum of 2 quarters · filed 2017-03-01 | -$71.22M derived: sum of 3 quarters · filed 2017-03-01 | -$63.27M 10-K · filed 2017-03-01 | ||||
| 2014-09-30 | -$2.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$93.42M derived: sum of 2 quarters · filed 2015-11-09 | -$85.48M 10-Q · filed 2015-11-09 | -$82.19M derived: sum of 4 quarters · filed 2016-02-29 | -$129.98M 10-Q · filed 2014-11-10 | |||
| 2014-06-30 | -$90.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | -$82.71M 10-Q · filed 2015-08-10 | -$79.42M derived: sum of 3 quarters · filed 2016-02-29 | -$77.19M derived: sum of 4 quarters · filed 2016-02-29 | -$127.21M 10-Q · filed 2014-08-11 | |||
| 2014-03-31 | $7.94M 10-Q · filed 2015-05-11 | $11.24M derived: sum of 2 quarters · filed 2016-02-29 | $13.46M derived: sum of 3 quarters · filed 2016-02-29 | -$6.31M derived: sum of 4 quarters · filed 2016-02-29 | -$36.55M 10-Q · filed 2014-05-12 | |||
| 2013-12-31 | $3.29M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $5.52M derived: sum of 2 quarters · filed 2016-02-29 | -$14.25M derived: sum of 3 quarters · filed 2016-02-29 | -$41.53M 10-K · filed 2016-02-29 | ||||
| 2013-09-30 | $2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | -$17.55M derived: sum of 2 quarters · filed 2014-11-10 | -$44.82M 10-Q · filed 2014-11-10 | |||||
| 2013-06-30 | -$19.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$47.05M 10-Q · filed 2014-08-11 | ||||||
| 2013-03-31 | -$27.28M 10-Q · filed 2014-05-12 | |||||||
| 2012-12-31 | -$1.22M 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |